B2DB — Who said what, where, and when

Anders Hogner

Senior Director, Head of Computational Chemistry CVRM, AstraZeneca R&D

Anders Hogner is listed as Senior Director, Head of Computational Chemistry CVRM, AstraZeneca R&D. Anders spoke at Drug Discovery Chemistry Europe 2026 in November 2026 (panellist, “Panel Discussion: How are AI/ML Techniques Impacting Drug Discovery in Pharma?”). Speaks mainly at Hospitals and Health Care events.

Compiled from published conference agendas; not yet confirmed by Anders. Is this you? Claim this profile.

About

Anders Hogner PhD, is a drug hunter with +20 years’ experience in the pharmaceutical industry in the field of chemistry/computer aided drug design. Anders is currently head of Computational Chemistry in Medicinal Chemistry in Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D. Part of Anders role involves co-leading AstraZeneca’s CADD strategy, global lead of IT demands from the business, and part of team delivering AstraZeneca’s Augmented Drug Discovery environment. During 2017-2018 Anders also acted as interim head of Computational Chemistry for Respiratory, Inflammation and Autoimmunity (RIA) disease unit. He has proven-track record of impacting projects milestones through innovative approaches resulted in being named co-inventor on 3 clinical drug projects and ability to bring in new methodologies and collaborations. He is passionate about talent management, mentoring, and developing people to achieve key deliverables in a performance-driven setting.

Sessions at 1 conference

Drug Discovery Chemistry Europe 2026 11 November 2026 – 12 November 2026

Spoke alongside

People who have shared a session with Anders at events on B2DB.